An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
← catalyst calendarNCT06270719 · readout in 1,230 d
Sponsored by Sarepta Therapeutics, Inc. (industry) · SRPT — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
500estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-07 | actual | When the study began enrolling |
| Primary completion | 2029-12-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2038-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-21 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Duchenne Muscular Dystrophy
Interventions
- Genetic: Delandistrogene Moxeparvovec — also filed as SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS
- Drug: Standard of Care — also filed as Chronic glucocorticoid treatment
Primary outcomes
what the primary-completion date above is the date OFMean Change From Baseline in Time to Walk/Run 10 Meters (10MWR) (Calculated Velocity) at Month 12
measured Baseline, Month 12
Number of Participants Experiencing Acute Liver Injury (ALI)
measured Baseline through Month 12
Permalink · SRPT's whole pipeline · Catalyst calendar · Every registered study · What changed